Ghanshyam Ghelani, MD
Hematology & Oncology · Tyler, TXNPI 1407297385
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,049 of the $1,423 with a category attached, or 73.7%. It is spread thinly across 25 manufacturers, the largest accounting for just 15.9%. 2025 is the largest year on record at $885, 4.9 times the $180 reported in 2023. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 47 payments — averaging $30.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$226
- AbbVie$199
- Tempus AI, Inc$179
- Pfizer$110
- Lilly USA, LLC$95
- Sanofi-aventis U.S. LLC$85
- plus $529 from 19 others
What the payments were for
- Food & beverage$1,04974%
- Education$37426%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $226 |
| AbbVie | 2 | $199 |
| Tempus AI, Inc | 7 | $179 |
| Pfizer | 5 | $110 |
| Lilly USA, LLC | 1 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $85 |
| Novocure Inc. | 2 | $65 |
| Genentech USA, Inc. | 2 | $49 |
| Bayer | 2 | $48 |
| Novartis | 2 | $47 |
| Incyte Corporation | 2 | $43 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $27 |
| Array Biopharma Inc | 1 | $27 |
| Geron Corporation | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Sanofi | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $17 |
| AVEO Pharmaceuticals, Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
How this compares
$1,423 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron Hcl | 11 | $67 |
| Anastrozole | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tyler
- Habte YimerTyler$934K
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.